Berberine and Fatty Liver Disease: What the Trials Found

Berberine has been tested in several randomized trials in people with fatty liver disease, and the results do not all point the same way. A 2015 open-label trial reported a larger fall in liver fat when berberine was added to lifestyle change. A 2026 double-blind trial of 337 people with obesity found no difference from placebo in liver fat after six months. This page sets out each human trial, the pooled analyses, the explanations offered from laboratory work, the absorption data and the safety findings, with each number as the study abstract printed it. Berberine's other uses are covered on the Berberine Benefits hub.

Table of Contents

  1. Fatty Liver Disease Has a New Name
  2. Berberine Is an Alkaloid From Several Plants
  3. The 2015 Trial Added Berberine to Lifestyle Change
  4. The 2026 Placebo-Controlled Trial Found No Drop in Liver Fat
  5. Smaller Trials Gave Mixed Results
  6. The Pooled Analyses Report Gains With Caveats
  7. Berberine Ursodeoxycholate Is a Separate Compound
  8. Proposed Mechanisms Come Mostly From Animal and Cell Studies
  9. Little Berberine Reaches the Bloodstream
  10. Safety Findings in Trials and Laboratory Studies
  11. Approved Treatments and Lifestyle Change Provide the Context
  12. What Is Not Known
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Fatty Liver Disease Has a New Name

For decades, fat build-up in the liver that was not caused by heavy drinking was called nonalcoholic fatty liver disease (NAFLD). In 2023 a modified Delphi process led by three large pan-national liver associations, with 236 panelists from 56 countries, chose a new name: metabolic dysfunction-associated steatotic liver disease (MASLD). The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents. The new definition requires at least 1 of 5 cardiometabolic risk factors, and people with the condition who drink more (140-350 g/wk for females and 210-420 g/wk for males) were given a separate category, metabolic and alcohol related/associated liver disease. The inflamed form, steatohepatitis, kept its place as a concept (Rinella 2023).

The berberine trials below were run under the old name, the new name, or a third term, metabolic dysfunction-associated fatty liver disease. This page uses "fatty liver disease" for all of them.

The condition is common. A 2023 systematic review of 92 studies (N=9,361,716) gave an overall global prevalence of 30.05%, rising from 25.26% in 1990-2006 to 38.00% in 2016-2019 (Younossi 2023). It is not limited to heavier people: a 2020 meta-analysis found that within the affected population, 19·2% were lean and 40·8% were non-obese (Ye 2020). The Non-Alcoholic Fatty Liver Disease page covers the disease itself.

Back to Table of Contents

Berberine Is an Alkaloid From Several Plants

Berberine is an isoquinoline alkaloid present in Berberis species (the barberry genus), Coptis chinensis and Hydrastis canadensis (goldenseal) (Dumitru 2026). It is the core alkaloid of Coptis chinensis, known in traditional Chinese medicine as Huanglian (He 2026), and phytomedicines containing it have been used for centuries in Ayurvedic and traditional Chinese medicine (Ren 2021). A 2026 review describes it as among the most widely consumed metabolic-health supplements (Dumitru 2026). Its history and sources are covered on the Berberine herb page.

A 2026 review of berberine and the liver's energy factories draws a line that matters for this page: pure berberine is a different thing from whole barberry fruit, from uncharacterized botanical preparations, and from berberine ursodeoxycholate, a separate compound described further down (Rafiei 2026).

Back to Table of Contents

The 2015 Trial Added Berberine to Lifestyle Change

The first large trial was a randomized, parallel controlled, open-label study at three medical centers, published in PLoS One in 2015 (Yan 2015). It enrolled 184 eligible patients with nonalcoholic fatty liver disease and randomly assigned them to one of three arms for 16 weeks:

Liver fat. Compared with lifestyle intervention alone, berberine plus lifestyle intervention produced a significant reduction of hepatic fat content (52.7% vs 36.4%, p = 0.008).

Weight, insulin resistance and blood fats. The liver-fat result was paralleled by better improvement in body weight, the homeostasis model assessment of insulin resistance (HOMA-IR) score and serum lipid profiles (all p<0.05). Berberine was more effective than pioglitazone 15 mg once a day in reducing body weight and improving the lipid profile.

Side effects and blood levels. Berberine-related adverse events were mild and mainly in the digestive system. Serum and urine berberine concentrations in the treated patients were 6.99 ng/ml and 79.2 ng/ml.

The animal arm. The same paper also gave berberine to an animal model of the disease: in those animals berberine located favorably in the liver and altered liver gene expression related to metabolism.

A follow-up analysis of the same trial measured 256 serum lipid molecular species in 41 patients in the berberine group and 39 in the lifestyle-only group. Berberine induced a substantially greater change in serum lipid species than lifestyle intervention alone and markedly decreased serum levels of ceramide and ceramide-1-phosphate; the authors proposed that this change in circulating ceramides may underlie the improvement in the liver (Chang 2016).

Two features limit how far this trial reaches. It was open-label, so patients and staff knew who took berberine, and the comparison arm received no placebo.

Back to Table of Contents

The 2026 Placebo-Controlled Trial Found No Drop in Liver Fat

The largest trial so far, published in JAMA Network Open in 2026, was multicenter and double-blind (Lei 2026). It enrolled diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease at 11 hospitals in China between July 6 and December 29, 2023, with 6 months of follow-up. Of 337 randomized participants (mean age 41.8 years; 221 [65.6%] male), 169 received oral berberine 1 g per day and 168 a matching placebo. Mean adherence was 90.3% for berberine and 90.7% for placebo.

Primary outcomes: no difference. The two primary outcomes, measured by computed tomography, were the change in visceral (belly) fat area and the change in liver fat content. No significant differences were observed between study arms for visceral fat area (1.4% [97.5% confidence interval, -2.4% to 5.2%]) or liver fat content (0.9% [97.5% confidence interval, -0.4% to 2.1%]).

Secondary outcomes. Berberine was associated with larger reductions than placebo in low-density lipoprotein (LDL) cholesterol (-7.72 mg/dL), apolipoprotein B (-3.42 mg/dL) and high-sensitivity C-reactive protein, an inflammation marker (-0.072 mg/dL), but not in the other secondary outcomes, which covered glucose, lipid and inflammation measures. Post hoc analyses suggested the larger falls in low-density lipoprotein cholesterol, apolipoprotein B and high-sensitivity C-reactive protein were consistent in people who started with higher high-sensitivity C-reactive protein.

Safety. The incidence of adverse events was similar between study arms. The authors concluded that 6 months of berberine at 1 g a day "had an excellent safety profile" but did not reduce visceral fat area or liver fat content.

A 2026 review of berberine and liver mitochondria summed up the human evidence as mixed, noting that a recent placebo-controlled trial found no significant reduction in liver fat with pure berberine (Rafiei 2026).

Back to Table of Contents

Smaller Trials Gave Mixed Results

Koperska 2024 (randomized, double-blind, placebo-controlled). Seventy people with metabolic dysfunction-associated fatty liver disease were assigned 1:1 to berberine 1500 mg per day or placebo for 12 weeks. Compared with placebo, the berberine group had a statistically significant decrease in alanine aminotransferase (ALT), a liver enzyme (p=0.0105), and in the de Ritis ratio (p=0.0011), and a significant difference in the change in total cholesterol (p=0.0009). There were no significant differences in other lipid and glucose parameters. Trunk fat fell in both groups (berberine p=0.0185, placebo p=0.0323). The authors wrote that longer trials are required to assess the effect fully (Koperska 2024).

Koperska 2025 (same design, 70 people, 1500 mg per day, 12 weeks). A second report from the same trial looked at blood vessels: vascular endothelial growth factor rose in the berberine group, no statistically significant differences were observed in arterial stiffness between the berberine and placebo groups, and no serious adverse events were reported (Koperska 2025).

Nejati 2022 (randomized, no placebo). Fifty patients were assigned to berberine (n = 25) or no berberine (n = 25); the abstract gives the berberine dose as 6.25 g per day, and both groups had received lifestyle training on diet and physical activity. Compared with the control group, berberine had no significant effect on triglyceride (P = 0.350), total cholesterol (P = 0.120), high-density lipoprotein (P = 0.401), low-density lipoprotein (P = 0.100), fasting blood glucose (P = 0.055), the liver enzymes alkaline phosphatase (P = 0.109), serum glutamic-oxaloacetic transaminase (P = 0.366) and serum glutamic pyruvic transaminase (P = 0.436), or body weight (P = 0.494). The authors concluded that berberine "was not associated with a significant decrease in lipid profile, fasting blood glucose, or liver enzymes" (Nejati 2022).

Xie 2011 (randomized, Chinese-language report with an English abstract). Sixty patients with newly diagnosed type 2 diabetes and fatty liver disease received berberine or a comparison preparation for 12 weeks. On liver ultrasound the effective rate was 70% with berberine and 73.3% with the comparison. Liver enzymes, cholesterol, triglycerides and blood-viscosity measures fell from baseline in the berberine group and high-density lipoprotein rose, but the two groups did not differ from each other (Xie 2011). The abstract does not give the berberine dose.

Back to Table of Contents

The Pooled Analyses Report Gains With Caveats

Wei 2016. Six randomized controlled trials with 501 patients. Berberine groups had significantly greater falls in total cholesterol, low-density lipoprotein, alanine aminotransferase, 2-hour glucose and hemoglobin A1c; insulin resistance and imaging results were described rather than pooled. The authors noted "the limitation of number and quality of trials included" (Wei 2016).

Nie 2024. Ten randomized trials with 811 patients. Berberine reduced alanine aminotransferase (standardized mean difference -0.72), aspartate aminotransferase (-0.79), gamma-glutamyl transpeptidase (-0.62), triglycerides (-0.59), total cholesterol (-0.74), low-density lipoprotein cholesterol (-0.53), the insulin-resistance score (-1.56) and body mass index (-0.58). The difference in high-density lipoprotein cholesterol was not significant (P = 0.11). Only mild gastrointestinal adverse events were reported, and the authors described berberine as showing "promise as an adjunct therapy" (Nie 2024).

Zhu 2025. Of 487 screened studies, 22 were included: 4 clinical and 18 preclinical. The clinical result the abstract reports is a significant fall in fasting blood glucose (effect size 0.53, 95% confidence interval 0.04-1.01); the benefits on liver enzymes and lipids came from the animal studies, with significant heterogeneity in some outcomes (Zhu 2025).

Asbaghi 2020. Twelve randomized trials, not limited to fatty liver disease. Berberine lowered body weight (-2.07 kg), body mass index (-0.47 kg/m2), waist circumference (-1.08 cm) and C-reactive protein (-0.42 mg/L), but had no significant effect on alanine aminotransferase (P = 0.160) or aspartate aminotransferase (P = 0.311) (Asbaghi 2020).

Network meta-analyses of herbal products. A 2024 analysis of 37 trials (2509 patients) compared seven natural products; artichoke leaf extract and naringenin performed better than the others, berberine included (Liu 2024). A 2026 analysis of 131 trials (n = 9191) found significant falls with berberine in aspartate aminotransferase (mean difference -19.63; P < .01) and gamma-glutamyl transpeptidase (mean difference -9.74; P = .01); for liver stiffness, only curcumin and pomegranate were statistically significant, and the authors called for cautious interpretation given formulation and regulatory inconsistencies (Chen Liang 2026). Its companion analysis of 123 trials (n = 8595) listed berberine only within a combination with tocotrienols and green coffee, rated confidence low for most outcomes, and described herbal products as possible adjuncts, "not substitutes for approved treatments" (Sairaj 2026).

Overviews. A 2025 overview of 54 systematic reviews found berberine improved 86.67% (13/15) of fatty liver disease outcomes, but flagged a high overlap of primary studies in the fatty liver reviews; of all reviews rated, only one was high quality, eight low and forty-five very low (Shi 2025). A 2024 systematic review of 9 clinical and 64 pre-clinical studies reported that human studies showed a measurable reduction of liver fat and better lipid and liver-enzyme profiles, and that its formulation needs improving to raise bioavailability (Ionita-Radu 2024).

Animal studies only. A 2021 meta-analysis pooled 31 animal studies (566 animals). Cholesterol, triglycerides, liver enzymes and glucose measures were significantly restored in treated animals; the fall in the insulin-resistance score was not significant (P = 0.08). These are results in animals, not people (Ren 2021).

The pooled analyses searched the literature up to dates between March 2016 and September 2025, before the 2026 placebo-controlled trial was published.

Back to Table of Contents

Berberine Ursodeoxycholate Is a Separate Compound

Berberine ursodeoxycholate (development code HTD1801) is an ionic salt of berberine and ursodeoxycholic acid, a bile acid. It is an investigational drug, and its trial results are not results for plain berberine.

Phase 2 trial in fatty liver disease with type 2 diabetes. One hundred people with presumed steatohepatitis and diabetes received one of two doses or placebo for 18 weeks, with liver fat measured by magnetic resonance imaging proton density fat fraction. At 1000 mg twice a day, liver fat fell more than on placebo (mean absolute decrease -4.8% vs. -2.0%, p = 0.011), with improved glycemic control, lower liver enzymes and significant weight loss. Diarrhea and abdominal discomfort were the most frequently reported adverse events (Harrison 2021).

Secondary analysis. In the same 100 patients, 52% of treated patients met the imaging response criteria compared with 24% on placebo (P<0.05). In golden hamsters fed a high-fat diet, the compound improved liver scarring under the microscope; that part is an animal result (Wong 2025).

Type 2 diabetes trial. In a 12-week phase 2 trial of 113 people with type 2 diabetes in China, the 1000 mg twice-daily dose lowered hemoglobin A1c, and reductions were observed in lipids and markers of liver injury. Treatment-emergent adverse events, generally mild, occurred in 59 patients (52.2%) overall (Ji 2025).

Back to Table of Contents

Proposed Mechanisms Come Mostly From Animal and Cell Studies

AMP-activated protein kinase and fat synthesis. In mice fed a high-fat diet and in two liver cell lines, berberine switched on AMP-activated protein kinase (AMPK), the cell's energy sensor, and lowered stearoyl-CoA desaturase 1, an enzyme that builds fat; the same enzyme was raised in liver tissue from patients with fatty liver disease and in obese mice (Zhu 2019). The link between AMP-activated protein kinase and berberine's wider effects is covered in the AMP-Activated Protein Kinase deep dive.

Gut bacteria. In mice on a methionine-choline-deficient diet, berberine raised the gut bacterium Akkermansia muciniphila and protected the intestinal barrier; wiping out gut bacteria with antibiotics weakened its effect (Xu 2025). A different mouse study pointed the other way: berberine curbed mitochondrial complex I in the gut and liver of mice, and the authors concluded this process was independent of intestinal bacteria (Yu 2021). The gut health deep dive covers berberine's wider effects on gut microbes.

Bile acids. In mice on a high-fat diet, oral berberine inhibited a bacterial enzyme that breaks down bile acids, raised tauro-conjugated bile acids, activated the intestinal farnesoid X receptor and lowered the liver's fat transporter Cd36; it did not protect mice lacking that intestinal receptor (Sun 2017). In a high-fat, high-fructose mouse model, berberine reduced liver fat, restored bile acid balance and lowered genes linked to scarring (Wang 2021).

Low-density lipoprotein receptor. In ApoE-deficient mice on a high-fat diet, berberine reduced liver fat build-up, and in cultured liver cells it raised the low-density lipoprotein receptor and lowered proprotein convertase subtilisin/kexin type 9, a protein involved in cholesterol handling (Ma 2021). The cholesterol deep dive covers the human lipid trials.

A contrary animal finding. Not every laboratory result runs in one direction. In liver cells and in mice fed a normal diet, berberine's activation of AMP-activated protein kinase increased the fat transporter fatty acid translocase CD36, and liver triglyceride levels rose; silencing CD36 in the liver prevented the rise (Choi 2017).

In people. The human mechanistic data are thin: the 2016 lipid-profiling analysis found lower blood ceramides with berberine (Chang 2016), and a 2026 review noted that no included trial directly measured liver mitochondrial function (Rafiei 2026).

Back to Table of Contents

Little Berberine Reaches the Bloodstream

In a human pharmacokinetic study, berberine displayed low oral bioavailability, and females had a 2.8-fold higher area under the curve (total exposure) and a 3.6-fold higher peak level than males (P < 0.001). The liver enzyme cytochrome P450 2D6 (CYP2D6) affected berberine metabolism only in females, while a genetic shortfall in the uptake transporter that carries berberine into cells did not change berberine levels in humans (Blöcher 2025).

The measured levels are small. In the 2015 fatty liver trial, serum berberine was 6.99 ng/ml in treated patients (Yan 2015). A 2026 review gives oral bioavailability of 0.68% in rats and low ng/mL plasma concentrations in humans (Dumitru 2026), and another 2026 review gives a figure of less than 1% (He 2026). One mouse study proposed that because so little is absorbed, berberine's main site of action is the gut (Sun 2017).

Back to Table of Contents

Safety Findings in Trials and Laboratory Studies

Digestive side effects. In the fatty liver trials, adverse events were mild and mainly digestive (Yan 2015), the incidence of adverse events was similar to placebo (Lei 2026), and no serious adverse events were reported (Koperska 2025). In a meta-analysis of placebo-controlled cholesterol trials, the 12 studies that reported gastrointestinal adverse events found them tending to be more frequent with berberine than placebo (2-23% vs 2-15%), and no serious adverse events were reported in the 16 studies that reported adverse events (Blais 2023).

Drug interactions measured in people. In a randomized crossover study, healthy men took berberine 300 mg three times a day for 2 weeks. Cytochrome P450 2D6 activity fell (the urinary dextromethorphan ratio rose ninefold), the losartan ratio doubled (lower cytochrome P450 2C9 activity), and midazolam exposure rose 40%, showing inhibition of cytochrome P450 3A4. The authors concluded that drug-drug interactions need attention when berberine is given (Guo 2012). A 2012 systematic review of clinical studies rated goldenseal/berberine as a weak inhibitor of cytochrome P450 3A4 and 2D6 (Hermann 2012). A 2026 review names increased cyclosporine exposure in kidney-transplant recipients as the clinical anchor (total exposure up 34.5%; trough levels 29.3% above control) and lists additive effects with drugs that lower blood sugar, lower blood pressure or prolong the QT interval (Dumitru 2026).

Newborns and pregnancy. In laboratory tests berberine displaced bilirubin from its carrier protein, albumin, about tenfold more strongly than phenylbutazone, a known potent displacer, and in adult rats a week of daily injections raised unbound and total bilirubin. The paper noted that the berberine-rich herb huanglian was reported to pose some risk of kernicterus (bilirubin brain damage) in jaundiced newborn infants, and its author concluded that such herbs are "best avoided in jaundiced neonates and pregnant women" (Chan 1993).

Liver injury. The records gathered for this page contain no human case report of liver injury from berberine. The one liver warning sign among them is the mouse finding in which berberine increased liver triglycerides through CD36 (Choi 2017). Berberine's dosing and cautions are covered on the Dosing, Forms and Cautions page.

Back to Table of Contents

Approved Treatments and Lifestyle Change Provide the Context

Two drugs in these records have approval for the inflamed, scarred stage of the disease. Resmetirom has been approved for noncirrhotic adults with moderate to severe liver fibrosis, along with diet and exercise (Osta 2025). In its phase 3 trial of 966 patients with biopsy-confirmed steatohepatitis, the steatohepatitis resolved without worsening fibrosis in 25.9% (80 mg) and 29.9% (100 mg) versus 9.7% on placebo at week 52, and fibrosis improved by at least one stage in 24.2% and 25.9% versus 14.2% (Harrison 2024). Semaglutide received accelerated U.S. Food and Drug Administration approval in August 2025 for steatohepatitis with moderate-to-advanced fibrosis; at 72 weeks, resolution without worsening fibrosis was 62.9% vs. 34.3% on placebo and fibrosis reduction 36.8% vs. 22.4%. The November 2025 guidance update states that lifestyle modification "remains the cornerstone" of care (Bansal 2026).

These drug trials measured liver biopsy outcomes. The plain-berberine trials measured liver fat, liver enzymes, blood fats and weight, so the outcomes differ, and no trial in the records gathered for this page tested berberine against resmetirom or semaglutide. The one drug comparison in a berberine fatty liver trial is pioglitazone 15 mg once a day, which berberine exceeded for weight and blood fats (Yan 2015). A 2026 network meta-analysis described herbal products as possible adjuncts, "not substitutes for approved treatments" (Sairaj 2026).

Back to Table of Contents

What Is Not Known

Back to Table of Contents

Key Research Papers

  1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PubMed PMID: 37363821
  2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. PubMed PMID: 36626630
  3. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al.. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739-752. PubMed PMID: 32413340
  4. Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al.. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015;10(8):e0134172. PubMed PMID: 26252777
  5. Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, et al.. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med. 2016;14:266. PubMed PMID: 27629750
  6. Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, et al.. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(1):e2554152. PubMed PMID: 41543854
  7. Koperska A, Moszak M, Seraszek-Jaros A, Bogdanski P, Szulinska M. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial. J Physiol Pharmacol. 2024;75(3):10.26402/jpp.2024.3.06. PubMed PMID: 39042390
  8. Koperska A, Miller-Kasprzak E, Seraszek-Jaros A, Musialik K, Bogdański P, Szulińska M. The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial. Nutrients. 2025;17(22):3585. PubMed PMID: 41305635
  9. Nejati L, Movahedi A, Salari G, Moeineddin R, Nejati P. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. Med J Islam Repub Iran. 2022;36:39. PubMed PMID: 36128280
  10. Xie X, Meng X, Zhou X, Shu X, Kong H. [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong Yao Za Zhi. 2011;36(21):3032-5. PubMed PMID: 22308697
  11. Wei X, Wang C, Hao S, Song H, Yang L. The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evid Based Complement Alternat Med. 2016;2016:3593951. PubMed PMID: 27446224
  12. Nie Q, Li M, Huang C, Yuan Y, Liang Q, Ma X, et al.. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024;22(1):225. PubMed PMID: 38429794
  13. Zhu W, Yang L, Dai Y, Wang H, Zhou J, Xia L, et al.. Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research. Front Pharmacol. 2025;16:1460643. PubMed PMID: 40949129
  14. Asbaghi O, Ghanbari N, Shekari M, Reiner Ž, Amirani E, Hallajzadeh J, et al.. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43-49. PubMed PMID: 32690176
  15. Liu H, Li Y, Jin Y, Li X, Wang D, Yu X, et al.. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials. Phytother Res. 2024;38(7):3801-3824. PubMed PMID: 38886838
  16. Chen Liang A, Cruz Castillo Y, Fermin Madera MD, Sairaj RT, Medina J, Moreno Díaz TA, et al.. Comparative Efficacy of Herbal Products for Improving Liver Enzymes and Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis. Gastro Hep Adv. 2026;5(9):101045. PubMed PMID: 42597704
  17. Sairaj RT, Chen Liang A, Cruz Castillo Y, Fermin Madera MD, Medina J, Moreno Díaz TA, et al.. Comparative Efficacy of Herbal Products on Metabolic Parameters in Metabolic-Dysfunction Associated Liver Disease: A Systematic Review and Network Meta-Analysis. Gastro Hep Adv. 2026;5(10):101040. PubMed PMID: 42668494
  18. Shi L, Wang W, Jing C, Hu J, Liao X. Berberine and health outcomes: an overview of systematic reviews. BMC Complement Med Ther. 2025;25(1):147. PubMed PMID: 40269802
  19. Ionita-Radu F, Patoni C, Nancoff AS, Marin FS, Gaman L, Bucurica A, et al.. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature. Int J Mol Sci. 2024;25(8):4201. PubMed PMID: 38673787
  20. Ren S, Ma X, Wang R, Liu H, Wei Y, Wei S, et al.. Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. Front Pharmacol. 2021;12:742465. PubMed PMID: 34566663
  21. Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, et al.. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021;12(1):5503. PubMed PMID: 34535644
  22. Wong VW, Neff GW, Di Bisceglie AM, Bai R, Cheng J, Yu M, et al.. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol. 2025;31(3):1071-1083. PubMed PMID: 40258699
  23. Ji L, Ma J, Ma Y, Cheng Z, Gan S, Yuan G, et al.. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2025;8(3):e2462185. PubMed PMID: 40029660
  24. Rafiei H, Omidian K, Tolentino M, Jafari A, Bahari H, Khalafi M. Berberine as a Mitochondrial Metabolic Reprogrammer in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Adaptive Energetic Stress, Quality Control, and Translational Limitations. Nutrients. 2026;18(20):3366. PubMed PMID: 42942937
  25. Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, et al.. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192-204. PubMed PMID: 31226399
  26. Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, et al.. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol. 2017;91(2):110-122. PubMed PMID: 27932556
  27. Xu J, Lao Y, Zhang W, Chen L, Zhang H, Liu H, et al.. Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila. J Nutr Biochem. 2025;146:110069. PubMed PMID: 40816629
  28. Yu M, Alimujiang M, Hu L, Liu F, Bao Y, Yin J. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. Int J Biol Sci. 2021;17(7):1693-1707. PubMed PMID: 33994854
  29. Wang Y, Tai YL, Zhao D, Zhang Y, Yan J, Kakiyama G, et al.. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells. 2021;10(2):210. PubMed PMID: 33494295
  30. Ma CY, Shi XY, Wu YR, Zhang Y, Yao YH, Qu HL, et al.. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Ann Transl Med. 2021;9(20):1517. PubMed PMID: 34790723
  31. Choi YJ, Lee KY, Jung SH, Kim HS, Shim G, Kim MG, et al.. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol. 2017;316:74-82. PubMed PMID: 28038998
  32. Blöcher JA, Meyer-Tönnies MJ, Morof F, Rönnpagel V, Bethmann J, Vollmer M, et al.. Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans. Clin Pharmacol Ther. 2025;117(1):250-260. PubMed PMID: 39488825
  33. He H, Wu S, Yi J. Berberine from Traditional Chinese Medicine in Liver Diseases: From Steatosis to Fibrosis and Hepatic Malignancies. Am J Chin Med. 2026;54(6):1721-1748. PubMed PMID: 42623127
  34. Dumitru CN, Marcu T, Dumitru AO, Tudor SS, Ferțu ID, Elisei AM, et al.. Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review. Pharmaceuticals (Basel). 2026;19(8):1313. PubMed PMID: 42653808
  35. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-7. PubMed PMID: 21870106
  36. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012;78(13):1458-77. PubMed PMID: 22855269
  37. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201-8. PubMed PMID: 8513024
  38. Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023;83(5):403-427. PubMed PMID: 36941490
  39. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al.. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: 38324483
  40. Osta EG, Saenz F, Jaganathan S, Thomas C, Tsai E, Surabhi V, et al.. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective. Radiographics. 2025;45(12):e240221. PubMed PMID: 41231713
  41. Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. PubMed PMID: 41201884

PubMed Topic Searches

  1. PubMed: Berberine and fatty liver disease, randomized trials
  2. PubMed: Berberine and MASLD
  3. PubMed: Berberine ursodeoxycholate

Back to Table of Contents

Connections

Back to Table of Contents